产品
编 号：F740883
分子式：C18H23N5O4
分子量：373.41
分子式：C18H23N5O4
分子量：373.41
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 368434-98-4
产品详情
生物活性：
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 μM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia.
体内研究：
PCSK9-IN-10 (30 mg/kg；口服；每天一次，持续 8 周) 降低 ApoE KO 小鼠的总胆固醇 (TC) 和动脉粥样硬化斑块大小。Animal Model:Eight weeks old male ApoE KO mice
Dosage:30 mg/kg
Administration:P.o.; once a day for 8 weeks
Result:Inhibited both hepatic and serum PCSK9 content obviously and reduced reduced atherosclerotic plaque size.
体外研究：
PCSK9-IN-10 (compound 3s) (0, 2.5, 5, 12.5, 25 μM; 24 h) 以剂量依赖性方式显著降低 PCSK9 蛋白表达并增加 LDL 受体 (LDLR) 的表达。
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 μM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia.
体内研究：
PCSK9-IN-10 (30 mg/kg；口服；每天一次，持续 8 周) 降低 ApoE KO 小鼠的总胆固醇 (TC) 和动脉粥样硬化斑块大小。Animal Model:Eight weeks old male ApoE KO mice
Dosage:30 mg/kg
Administration:P.o.; once a day for 8 weeks
Result:Inhibited both hepatic and serum PCSK9 content obviously and reduced reduced atherosclerotic plaque size.
体外研究：
PCSK9-IN-10 (compound 3s) (0, 2.5, 5, 12.5, 25 μM; 24 h) 以剂量依赖性方式显著降低 PCSK9 蛋白表达并增加 LDL 受体 (LDLR) 的表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备